Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Anti-ETAR (endothelin A receptor) antibodies and anti-CXCR3 (C-X-C motif chemokine receptor 3) antibodies are types of non-HLA (human leukocyte antigens) antibodies that could have some influence on the course of glomerulonephritis. The authors aimed to study the influence of these antibodies' levels on the course of specific glomerulonephritis types. We evaluated the anti-ETAR and anti-CXCR3 antibody levels in the serum of patients with membranous nephropathy (n = 18), focal and segmental glomerulosclerosis (FSGS) (n = 25), systemic lupus erythematosus (n = 17), IgA nephropathy (n = 14), mesangiocapillary glomerulonephritis (n = 6), anti-neutrophil cytoplasmic antibodies (c-ANCA) vasculitis (n = 40), and perinuclear anti-neutrophil cytoplasmic antibodies (p-ANCA) vasculitis (n = 16), and we compared their levels with the control group (n = 22). Next, we observed the patients' clinical parameters (serum creatinine, albumin, total protein) for 2 years and checked the correlation of the clinical course markers with basic receptor antibody level. Our results indicate lower anti-ETAR antibody levels in patients with FSGS and IgA nephropathy compared to the control group. Both types of antibodies correlated with creatinine levels after 2 years of observation in IgA nephropathy. Both types of antibodies seemed to negatively influence the total protein and albumin levels in systemic lupus erythematosus. : This prospective observation showed that anti-ETAR and anti-CXCR 3 antibody levels are connected with the course of IgA nephropathy and lupus nephritis.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11679591 | PMC |
| http://dx.doi.org/10.3390/jcm13247752 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
IGLV3-21-directed bispecific antibodies activate T cells and promote killing in a high-risk subset of chronic lymphocytic leukemia.
Haematologica
September 2025
Division of Medical Oncology, University Hospital Basel, Basel, Switzerland; Laboratory of Translational Immuno-Oncology, Department of Biomedicine, University and University Hospital Basel, Basel.
We previously used a disease-specific B cell receptor (BCR) point mutation (IGLV3-21R110) for selective targeting of a high-risk subset of chronic lymphocytic leukemia (CLL) with chimeric antigen receptor (CAR) T cells. Since CLL is a disease of the elderly and a significant fraction of patients is not able to physically tolerate CAR T cell treatment, we explored bispecific antibodies as an alternative for precision targeting of this tumor mutation. Heterodimeric IgG1-based antibodies consisting of a fragment crystallizable region (Fc) attached to both an anti-IGLV3-21R110 Fab and an anti-CD3 (UCHT1) single chain variable fragment (R110-bsAb) selectively killed cell lines engineered to express high levels of the neoepitope as well as primary CLL cells using healthy donor and CLL patient-derived T cells as effectors.
View Article and Find Full Text PDFPACAP versus CGRP in migraine: From mouse models to clinical translation.
Cephalalgia
September 2025
Department of Molecular Physiology and Biophysics, University of Iowa, Iowa City, IA, USA.
Migraine is a complex neurological disorder involving multiple neuropeptides that modulate nociceptive and sensory pathways. The most studied peptide is calcitonin gene-related peptide (CGRP), which is a well-established migraine trigger and therapeutic target. Recently, another peptide, pituitary adenylate cyclase-activating polypeptide (PACAP), has emerged as an alternative target for migraine therapeutics.
View Article and Find Full Text PDFEplet mismatch analysis in kidney transplantation: from concept to clinical practice.
Clin Transplant Res
September 2025
Department of Laboratory Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Eplet mismatch analysis offers a refined approach to assessing donor-recipient compatibility in kidney transplantation, surpassing conventional antigen-level human leukocyte antigen (HLA) matching in predicting immunologic outcomes. By identifying polymorphic amino acid residues on HLA molecules recognized by B cell receptors, this method quantifies immunologic risk. Clinical studies demonstrate that high eplet mismatch loads, particularly at HLA-DQ, are strongly associated with donor-specific antibody development, antibody-mediated rejection, and reduced graft survival.
View Article and Find Full Text PDFClinicopathological Features of Non-HPV-associated Common Differentiated Penile Squamous Cell Carcinoma: A Study of 55 Patients.
Appl Immunohistochem Mol Morphol
September 2025
Department of Pathology, Yantai Yuhuangding Hospital of Qingdao University, Yantai, P. R. China.
To investigate the clinicopathological characteristics of non-HPV-related common differentiated penile squamous cell carcinoma, and to observe and analyze the changes of TP53 gene and the expression and significance of TP53, P16, programmed death-ligand 1 (PD-L1), epidermal growth factor receptor (EGFR), androgen receptor (AR), human epidermal growth factor receptor-2 (HER2), and Ki67 proteins in tumor tissue. A total of 65 patients with penile squamous cell carcinoma diagnosed from May 2008 to May 2020 in Yantai Yuhuangding Hospital were retrospectively analyzed, and tumors were confirmed as non-HPV-associated common differentiated squamous cell carcinoma of the penis with negative HPV molecular tests in 55 patients. The relevant clinicopathological data of 55 patients were collected, and the TP53 gene mutation was detected by applying first-generation sequencing technology.
View Article and Find Full Text PDFEstimands for Early-Phase Dose Optimization Trials in Oncology.
Biom J
October 2025
Novella Clinical Full Service, IQVIA, Melbourne, Australia.
Phase I dose escalation trials in oncology generally aim to find the maximum tolerated dose. However, with the advent of molecular-targeted therapies and antibody drug conjugates, dose-limiting toxicities are less frequently observed, giving rise to the concept of optimal biological dose (OBD), which considers both efficacy and toxicity. The estimand framework presented in the addendum of the ICH E9(R1) guidelines strengthens the dialogue between different stakeholders by bringing in greater clarity in the clinical trial objectives and by providing alignment between the targeted estimand under consideration and the statistical analysis methods.
View Article and Find Full Text PDF